COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Thrombocytopathy in Gaucher Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01344096
Recruitment Status : Unknown
Verified October 2016 by Rabin Medical Center.
Recruitment status was:  Recruiting
First Posted : April 28, 2011
Last Update Posted : October 28, 2016
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Rabin Medical Center

Brief Summary:

In Gaucher disease type I bleeding is a common presenting symptom, that may manifest itself as frequent nose bleeds, easy bruising but can also cause substantial bleeding after surgical or dental procedures and may occur in association with pregnancy or delivery . The bleeding tendency is usually considered to be secondary to thrombocytopenia However 50,000 platelets are enough in healthy people to give a normal bleeding time but are associated with significant bleeding tendencies in Gaucher patients. Bleeding tendency might be attributed by genetic inherited or Gaucher related coagulation factors abnormalities which in some cases stabilize with ERT. However, In other cases the etiology is an abnormality of platelet function. This thrombocytopathy has not been delineated and apart from a few aggregation studies, no systematic analysis has been published that convincingly shows the cause of the disturbed function. While, experience shows that enzyme replacement (ERT, i.e: imiglucerase, Cerezyme®) reduces this bleeding tendency, in part due to the improvement in the thrombocyte count and elevation in coagulation factors, it is less clear what effect ERT has on the thrombocytopathy. This has clinical significance when patients need to be prepared for surgery or delivery or in the event of a major bleed. There is no consensus as to how patients should be prepared or treated. Different centres use different approaches. When the procedure is elective ERT is appropriate but in other situations DDAVP, fresh frozen plasma and platelet infusion are possible treatments. Even activated factor VII has been used when bleeding was not controlled. As in any other coagulation abnormality, treatment should be tailored to the specific cause of the bleeding diathesis. The aim of this study is to define the etiology of platelet dysfunction in Gaucher patients.

Hypothesis: The investigators expect to see a difference between platelets activation profile among imiglucerase treated and untreated patients with at least a partial restoration of platelets function due to treatment commencement.

Condition or disease
Gaucher Disease Thrombocytopathy

Detailed Description:


Delineating the cause of the thrombocytopathy in Gaucher disease patients:

  1. Identifying thrombocytopathy among a cohort of 70 Gaucher patients managed (treated and untreated) in our clinic using a panel of platelets function tests.
  2. Understanding the etiology for platelets dysfunction in Gaucher disease.
  3. Evaluating the impact of Imiglucerase treatment duration and Gaucher disease severity on platelet function

Layout table for study information
Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A 1.5 Years Prospective Study Designed to Delineate the Cause of the Thrombocytopathy in Gaucher Disease Patients
Study Start Date : October 2010
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : November 2018

Primary Outcome Measures :
  1. Measure thrombocytopathy in a cohort of 70 Gaucher patients using a set of platelet function tests. [ Time Frame: 3 years ]
    • 70 Gaucher patients managed (treated and untreated controls) will be subjected to a panel of platelets function tests (aggregation test, closure time and FACS analysis).

Secondary Outcome Measures :
  1. Evaluating the impact of Imiglucerase treatment on platelet function [ Time Frame: 3 years ]
    Platelet function during the 3 years of study will be analyzed versus Imiglucerase treatment status and duration taking into consideration genotype, age at diagnosis, spleen status and Gaucher disease severity at treatment initiation

Biospecimen Retention:   Samples Without DNA
Blood Samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Gaucher disease patients treated and untreated wih Imiglucerase

Inclusion Criteria:

  • Gaucher disease patients
  • Patients who do not receive any medicine that affects platlats

Exclusion Criteria:

  • Treatment with enzyme replacement therapy other than Imiglucerase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01344096

Layout table for location contacts
Contact: Monica Weisz Hubshman, MD 972-3-9377522
Contact: Ian J Cohen, Prof.

Layout table for location information
Rambam Medical Center Not yet recruiting
Haifa, Israel
Contact: Hagit Baris, Prof    972-4-7771286   
Contact: Ian J Cohen, Prof   
Principal Investigator: Hagit Baris         
Rabin Medical Center Recruiting
Petach Tikva, Israel, 49100
Contact: Monica Weisz Hubshman, MD    972-3-9377522   
Contact: Ian J Cohen, Prof.   
Principal Investigator: Monica Weisz Hubshman, MD         
Sub-Investigator: Ian Cohen, Prof.         
Sponsors and Collaborators
Rabin Medical Center
Genzyme, a Sanofi Company
Layout table for investigator information
Study Chair: Ian J Cohen, Prof. Rabin Medical Center
Study Chair: Hagit Baris, MD Rambam Health Care Campus
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Rabin Medical Center Identifier: NCT01344096    
Other Study ID Numbers: RMC6088
GZGD02507 ( Other Grant/Funding Number: Genzyme )
First Posted: April 28, 2011    Key Record Dates
Last Update Posted: October 28, 2016
Last Verified: October 2016
Keywords provided by Rabin Medical Center:
Gaucher disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Gaucher Disease
Blood Platelet Disorders
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Hematologic Diseases